topic

Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells
Janet Lei, Egon J. Jacobus, William K. Taverner, Kerry D. Fisher, Silvio Hemmi, Katy West, Lorna Slater, Fred Lilley, Alice Brown, Brian Champion, Margaret R. Duffy, Len W. Seymour

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 55; DOI: 10.1186/s40425-018-0350-x
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
Kendall F. Moseley, Jarushka Naidoo, Clifton O. Bingham, Michael A. Carducci, Patrick M. Forde, Geoffrey T. Gibney, Evan J. Lipson, Ami A. Shah, William H. Sharfman, Laura C. Cappelli

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 104; DOI: 10.1186/s40425-018-0417-8
Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment
Grace Mahlbacher, Louis T. Curtis, John Lowengrub, Hermann B. Frieboes

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 10; DOI: 10.1186/s40425-017-0313-7
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients
Michael T. Tetzlaff, Kelly C. Nelson, Adi Diab, Gregg A. Staerkel, Priyadharsini Nagarajan, Carlos A. Torres-Cabala, Beth A. Chasen, Jennifer A. Wargo, Victor G. Prieto, Rodabe N. Amaria, Jonathan L. Curry

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 14; DOI: 10.1186/s40425-018-0323-0
Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma
Ian Lai, Srividya Swaminathan, Virginie Baylot, Adriane Mosley, Renumathy Dhanasekaran, Meital Gabay, Dean W. Felsher

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 125; DOI: 10.1186/s40425-018-0431-x
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors
Edward Hammond, Nicole M. Haynes, Carleen Cullinane, Todd V. Brennan, Darryn Bampton, Paul Handley, Tomislav Karoli, Fleur Lanksheer, Liwen Lin, Yiping Yang, Keith Dredge

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 54; DOI: 10.1186/s40425-018-0363-5
Ipilimumab induced digital vasculitis
Amrita Padda, Elena Schiopu, Justin Sovich, Vincent Ma, Ajjai Alva, Leslie Fecher

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 12; DOI: 10.1186/s40425-018-0321-2
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature
Francesco Sabbatino, Antonio Marra, Luigi Liguori, Giosuè Scognamiglio, Celeste Fusciello, Gerardo Botti, Soldano Ferrone, Stefano Pepe

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 126; DOI: 10.1186/s40425-018-0439-2
Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab
Haris Zahoor, Pedro C. Barata, Xuefei Jia, Allison Martin, Kimberly D. Allman, Laura S. Wood, Timothy D. Gilligan, Petros Grivas, Moshe C. Ornstein, Jorge A. Garcia, Brian I. Rini

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 107; DOI: 10.1186/s40425-018-0425-8
Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model
Yuri Kosinsky, Simon J. Dovedi, Kirill Peskov, Veronika Voronova, Lulu Chu, Helen Tomkinson, Nidal Al-Huniti, Donald R. Stanski, Gabriel Helmlinger

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 17; DOI: 10.1186/s40425-018-0327-9

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages